The OncoLens Research Network (ORN) is a dynamic, collaborative ecosystem that empowers cancer centers with curated, revenue-generating opportunities in clinical research, real-world data (RWD) initiatives, and quality improvement programs.
By bridging providers with life science partners, ORN transforms oncology care through intelligent collaboration, precision analytics, and streamlined execution.
HER2-Targeted Testing & Treatment in Breast Cancer
Supporting adoption of novel HER2-low testing protocols and expanding access to emerging targeted therapies.
Biomarker Testing Compliance
Enhancing adherence to NCCN and ASCO guidelines through automated prompts, dashboard tracking, and navigator alerts.
Radioligand Therapy Trials
Facilitating patient identification and trial enrollment for radioligand therapies in prostate and neuroendocrine tumors.
Prostate Cancer Patient Journey Mapping
Delivering AI-powered dashboards that visualize care pathways, identify delays, and optimize treatment sequencing.
What Sets ORN Apart
Curated Trial & Research Opportunities
OncoLens conducts in-depth pre-feasibility analyses before presenting any opportunity, ensuring alignment with your patient population, operational capacity, and strategic goals.
End-to-End Support
From pre-screening and patient identification to data analytics and reporting, OncoLens acts as your business development arm—reducing administrative burden while driving clinical and financial impact.
Hyper-Targeted Patient Identification
Leverage AI-powered tools to find patients with rare mutations, misdiagnoses, or unmet needs—ensuring no one is missed for potentially life-saving therapies.
